The estimated Net Worth of William K. Mc Vicar is at least $1.2 Milhão dollars as of 6 June 2022. William Vicar owns over 26,553 units of Salarius Pharmaceuticals stock worth over $42,485 and over the last 9 years he sold SLRX stock worth over $0. In addition, he makes $1,160,520 as Chairman of the Board at Salarius Pharmaceuticals.
William has made over 2 trades of the Salarius Pharmaceuticals stock since 2020, according to the Form 4 filled with the SEC. Most recently he bought 26,553 units of SLRX stock worth $5,045 on 6 June 2022.
The largest trade he's ever made was buying 26,553 units of Salarius Pharmaceuticals stock on 6 June 2022 worth over $5,045. On average, William trades about 2,518 units every 60 days since 2016. As of 6 June 2022 he still owns at least 26,553 units of Salarius Pharmaceuticals stock.
You can see the complete history of William Vicar stock trades at the bottom of the page.
Dr. William K. McVicar Ph.D. serves as Chairman of the Board of the Company. Dr. McVicar has served as a member of the board of directors of Salarius since the completion of the Merger in July 2019. Prior to completion of the Merger, Dr. McVicar served as a member of the board of directors of Flex Pharma since August 2017, and served as its chief executive officer from July 2017 to July 2019. Dr. McVicar joined Flex Pharma in April 2017 as President of Research & Development. Prior to joining Flex Pharma, Dr. McVicar served as executive vice president of pharmaceutical development, chief scientific officer and president during his tenure at Inotek Pharmaceuticals Corporation from September 2007 to April 2017. Dr. McVicar also held various positions at Sepracor, Inc., RPR Gencell, Novartis AG and the Gene and Cell Therapy Division of Rhone Poulenc Rorer. Dr. McVicar earned his B.S. in Chemistry from the State University of New York College at Oneonta and his Ph.D. in Chemistry from the University of Vermont.
As the Chairman of the Board of Salarius Pharmaceuticals, the total compensation of William McVicar at Salarius Pharmaceuticals is $1,160,520. There are no executives at Salarius Pharmaceuticals getting paid more.
William McVicar is 62, he's been the Chairman of the Board of Salarius Pharmaceuticals since 2020. There are 3 older and 5 younger executives at Salarius Pharmaceuticals. The oldest executive at Salarius Pharmaceuticals, Inc. is Arnold Hanish, 72, who is the Independent Director.
William's mailing address filed with the SEC is C/O SALARIUS PHARMACEUTICALS, INC., 2450 HOLCOMBE BLVD., SUITE X, HOUSTON, TX, 77021.
Over the last 5 years, insiders at Salarius Pharmaceuticals have traded over $0 worth of Salarius Pharmaceuticals stock and bought 487,662 units worth $209,636 . The most active insiders traders include David J. Arthur, Mark J Rosenblum, eArnold C Hanish. On average, Salarius Pharmaceuticals executives and independent directors trade stock every 40 days with the average trade being worth of $33,925. The most recent stock trade was executed by Tess Burleson on 7 June 2022, trading 27,700 units of SLRX stock currently worth $4,986.
Salarius Pharmaceuticals, Inc., a clinical-stage biotechnology company, focuses on developing epigenetic-based cancer treatments. The company's lead candidate is Seclidemstat (SP-2577), which is in Phase I/II clinical trial for the treatment of advanced solid tumors, including prostate, breast, and ovarian cancers, as well as Ewing sarcoma. It has a strategic partnership with The University of Utah Research Foundation for the exclusive license with respect to patent rights protecting SP-2577 and related compounds; HLB Life Sciences to develop, produce, manufacture, use, and sell the drug in South Korea; and Cancer Prevention and Research Institute of Texas for product development activities, as well as a research partnership with the Cancer Epigenetics Institute at Fox Chase Cancer Center to identify new indications and potential biomarkers for Seclidemstat (SP-2577). Salarius Pharmaceuticals, Inc. is headquartered in Houston, Texas.
Salarius Pharmaceuticals executives and other stock owners filed with the SEC include: